AVM Biotechnology
Business Services · Washington, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1749 Dexter Ave N, Seattle, Washington, ...Phone Number
(206) 906-9922Website
www.avmbiotech.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About AVM Biotechnology
AVM Biotechnology specializes in immunotherapy solutions for COVID-19, cancer, autoimmunity, and infectious diseases. The company is advancing AVM0703, a proprietary formulation designed to enhance the immune response by activating unique immune cells. Their mission focuses on developing treatments that leverage the body's immune system to save lives and improve health outcomes. AVM Biotechnology targets a range of clients, including patients in need of innovative cancer treatments and those suffering from autoimmune conditions.Explore more
AVM Biotechnology Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is AVM Biotechnology your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when AVM Biotechnology launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at AVM Biotechnology
Check if AVM Biotechnology has recently received funding, and reach out quickly before it becomes old news!
AVM Biotechnology, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on AVM Biotechnology recently announced quarterly report
Website visits: Recent activity has been detected on your website
Click to see if AVM Biotechnology had a recent Job posting/layoffs
Funding: Get notified immidiatlly once AVM Biotechnology has new funding data
Check out if AVM Biotechnology is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined AVM Biotechnology as Masked Content
Find 2 more new buyers
Compare Similar Companies to AVM Biotechnology
Compare insights from companies similar to AVM Biotechnology, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
AVM Biotechnology
<$5M
11-50
Private
$8.8M
2008
EL
Edward LoniewskiChief Medical Officer & Chief Marketing Officer
Company Profile Activity
Activity Insights
AVM Biotechnology is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
AVM Biotechnology is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about AVM Biotechnology.
AVM Biotechnology financials insights
Gather financial insights about AVM Biotechnology, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2011
Unspecified
$708K
2012
Series A
$880K
2014
Series B
$1.5M
2016
Private Equity
$5.5M
2020
Debt
$150K
AVM Biotechnology Tech Stack
A closer look at the technologies used by AVM Biotechnology
Most Recent Scoops
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
New Hire
Executive Move
Pearl Chan has been named Chief Financial Officer.
New Hire
Executive Move
New Hire
Executive Move
Executive Moves, New Hire
AVM Biotechnology News & Media
AVM Biotechnology Selected by the National Cancer Institute to Present at Bio Investor Forum 2023
SEATTLE--(BUSINESS WIRE)-- #AMSM--AVM Biotechnology to Present at Bio Investor Forum 2023AVM Biotechnology Announces that the National Cancer Institute has selected AVM Biotechnology as a Showcase Company for their 2023-2024 Small Business Innovation Research (SBIR) Investor Initiatives
SEATTLE--(BUSINESS WIRE)-- #AMSM--The National Cancer Institute has selected AVM Biotechnology as a 2023-2024 Showcase Company for its Small Business Innovation Investor InitiativesAVM Biotechnology Announces Twenty-Eight (28) Solid Tumor and Blood Cancer Patients have been Treated with Immunomodulatory AVM0703 through Expanded Access/Compassionate Use Programs
SEATTLE--(BUSINESS WIRE)-- #StrongerThanCancer--Immunomodulatory AVM0703 has been provided to 28 solid tumor and blood cancer patients under compassionate use/expanded access programs.NIH Awards AVM Biotechnology SBIR Grant to Study AVM0703 Combined with Standard of Care in Non-Hodgkin’s Lymphoma (NHL) to Improve Complete Response Rates Without Additional Toxicities
SEATTLE--(BUSINESS WIRE)-- #Oncology--NIH awards AVM Biotechnology SBIR grant to study AVM0703 combined with R-CHOP in NHL to improve complete response rates without additional toxicities
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding AVM Biotechnology
Sign Up For FreeTo access detailed company insights
AVM Biotechnology specializes in immunotherapy solutions for COVID-19, cancer, autoimmunity, and infectious diseases. The company is advancing AVM0703, a proprietary formulation designed to enhance the immune response by activating unique immune cells. Their mission focuses on developing treatments that leverage the body's immune system to save liv... Read More
